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Friedreich’s ataxia is the most common form of hereditary ataxia with autosomal 
recessive pattern. More than 96% of patients are homozygous for GAA repeat 
extension on both alleles in the first intron of FXN gene and the remaining 
patients have been shown to be heterozygous for a GAA extension in one allele 
and point mutation in other allele.
Materials & Methods
In this study, exons of 1, 2, 3, and 5 of frataxin gene were searched by single 
strand conformation polymorphism polymerase chain reaction (PCR-SSCP) in 
5 patients with GAA extension in one allele. For detection of exact mutation, 
samples with band shifts were sent for DNA sequencing. 
Results
Three novel point mutations were found in patients heterozygous for the GAA 
repeat expansion, p.S81A, p.Y123D, and p.S192C.
Conclusion
Our results showed that these point mutations in one allele with GAA extension 
in another allele are associated with FRDA signs. Thus, these results emphasize 
the importance of performing molecular genetic analysis for point mutations in 
FRDA patients. 
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ORIGINAL  ARTICLE
Introduction
Friedreich’s ataxia (FRDA) is the most prevalent autosomal recessive hereditary 
ataxia affecting approximately 1 in 50,000 individuals (1). The essential diagnostic 
criteria, as defined by Harding (2), comprised of onset before 25 years of age and 
within 5 years of onset, there is progressive ataxia of limbs and gait, absence of 
knee and ankle jerks and extensor plantar responses, and dysarthria after 5 years 
of symptom onset (3).
The majority of FRDA patients is homozygous for GAA repeat expansions within 
the first intron of the FXN gene (4). In normal alleles, the repeat has variation in 
size between 6 and 36 GAA, whereas in mutated alleles, the repeat length varies 
from 120 to 1700 (4-9). In patients who are heterozygous for the expanded allele 
(2-4%), nucleotide substitutions, small deletions, and insertions are found (10,11). 
We investigated five ataxia patients with heterozygosity for point mutations in 
FXN gene via PCR-SSCP analyses. In this study, we report three novel point 
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mutations, which have been identified in our patients, 
one at codon 81 in exon 2 (S81A), the second at codon 




We investigated 5 patients (3 females and 2 males) 
heterozygous for the GAA trinucleotide repeat 
genotype in the FRDA gene with a slowly progressive 
gait ataxia compatible with autosomal recessive 
inheritance. Twenty-five healthy controls (15 females 
and 10 males) matched for age, sex, and ethnicity, 
were selected. All of the patients and control group 
were informed on the aims of the study and gave their 
informed consents for the genetic analysis. Patients 
were diagnosed and referred for assessment by 
consultant neurologists.
Mutation analysis
Genomic DNA was isolated from whole blood using 
standard procedures. Repeat expansions were detected 
by PCR amplification of 250 ng DNA using primers 
5200 Eco and 5200 Not, together with the Expand 
Long Template PCR System (Roche, Mannheim, 
Germany), which was previously described (12-14). 
The GAA repeat length was calculated based on the 
size of the PCR product (457+3n bp, n= number of 
GAA triplets) (15).
Single-strand conformational polymorphism (SSCP) 
analysis was performed on the four main frataxin 
exons (exons of 1, 2, 3, and 5), including exon–intron 
boundaries (Table 1). Electrophoresis was done in 
different conditions of temperature and voltage for 
each PCR reaction. After electrophoresis, gel was 
stained with silver staining method (16). The SSCP 
variant bands were excised from the gel and directly 
sequenced by automated sequencing 3700 ABI 
machine (Macrogene Seoul, South Korea) (Fig. 1).
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The secondary structural characteristics and 
physicochemical properties (hydropathy index, 
flexibility index, and antigenic index) were determined 
by Protean (protein structure prediction and annotation) 
and the conservation of the amino acid changes was 
assayed using MEGALIGN program, which is part of 
the Lasergene V.6 software (DNASTAR, Inc. Madison, 
WI). The hedrophathy index was measured by Protean 
based on the Kyte-Doolitle method (17), which predicts 
the regional hydropathy of proteins by their amino acid 
sequence. Hydropathy values were assigned for all 
amino acids and then were averaged over a window size 
equal to 9. Results less than 0 are hydrophobic and more 
than 0 are hydrophilic. 
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Fig. 1. A) Single-strand conformation polymorphism 
(SSCP) analysis of exon 5 amplified products: Lane 
1 represents non-denatured DNA; Lane 2 represents 
the patient’s DNA, showing an abnormal band; lanes 
3, 4, 5, and 6 represent normal control DNAs. B) 
Sequencing result.
Results
Molecular analysis was performed for five patients with 
heterozygosity for the GAA repeat expansion and 25 
healthy controls. The size of GAA expansion observed 
in our compound heterozygous FRDA patients, ranged 
from 490 to 873. 
Three novel point mutations was found (Table 2) in 
three patients by PCR-SSCP, one at position c.241T>G 
resulting in the amino-acid exchange p.Ser81Ala, the 
second at position c.367T>G resulting in p.Tyr186Asp, 
and the third at position c.574A>T resulting in the amino-
acid exchange p. Ser192Cys within frataxin. These 
sequence alterations were not found in the controls. 
Table 2. Summary of Mutations Identified In The 
Study Subjects
Patient Exon Mutation Effect 
1 2 c.241T>G p.S81A
3 5 c.574A>T p.S192C
4 3 c.367T>G p.Y123D
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Discussion
FRDA is well defined by clinical criteria, including are 
flexia and onset before age 25. An inverse correlation 
was observed by Campuzano et al. between the amount 
of frataxin protein and the size of the GAA repeat on 
the smaller allele (15). Previous observations have 
shown a correlation between the length of the smaller 
allele and phenotypic severity (6,18). Therefore, the 
milder clinical presentation in subjects with smaller 
GAA repeat sizes is probably to be because of higher 
levels of frataxin present in such patients. Since the 
GAA expansion changes protein levels rather than 
function, examination of the few patients having point 
mutations in their FRDA gene will help to clarify the 
key functional domains of frataxin. It is supposed that 
the expanded allele can contribute to the phenotype 
in patients who are compound heterozygous for an 
expansion on one allele and a point mutation on the 
other, but we cannot quantify this contribution. So, 
although very rare, locus genetic heterogeneity exists 
in Friedreich’s ataxia. In addition, ataxia with vitamin 
E deficiency caused by mutations in the a-TTP gene is 
expressed as a Friedreich-like phenotype (19).
Various point mutations have been associated with 
milder and atypical phenotypes in heterozygous 
patients (20-22).
Patient 1 is a male who presented with an onset of 
symptoms at 9 years of age with asymmetric ataxia. 
Recent examination showed spinocerebellar ataxia, 
pes cavus, and reduced vibration sense. He was found 
to be heterozygous for an expanded FRDA allele 
of approximately 870 GAA repeats. Using SSCP 
analysis and sequencing, a point mutation of a T to 
a G at codon 81 was detected. c.241T>G sequence 
change is located at codon 81 and alters a moderately 
conserved serine, a polar amino acid, to alanine, a 
nonpolar amino acid, altering the hydropathy index 
from -0.733 to -0.444. 
Patient 3 is also a 22-year-old female. Onset of 
symptoms was at 14 years with gait disturbance. She 
had one allele in the expanded range of 620 repeats. 
SSCP analysis and sequencing revealed a single 
base substitution of a A to a T altering codon 192. 
c.574A>T sequence change is located at amino acid 
position 192. It changes a moderately conserved serine 
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acid position 186 in frataxin gene. It changes a highly 
conserved thyrosine (a hydrophobic amino acid) to 
aspartic acid (a hydrophilic amino acid), which changes 
the hydropathy index from -0.389 to -0.633 (Fig. 1). 
In conclusion, point mutations in FRDA that causes 
an absence of functional frataxin, are associated with 
a severe phenotype. Our results showed that these 
point mutations in one allele and GAA extension in 
another allele are associated with FRDA signs. Thus, 
these results emphasize the importance of performing 
molecular genetic analysis for point mutations in 
FRDA patients. 
(a hydrophilic amino acid) to cysteine (a hydrophilic 
amino acid), which changes the hydropathy index 
from 0.756 to 0.389. 
Patient 4 is a Caucasian female, who is currently 24 
years old, with an onset of symptoms at 15 years of age 
with frequent tripping. She has progressively worsening 
lower limb ataxia and currently uses a walking stick. 
She was also heterozygous for the expansion in FRDA 
with an expanded allele of 490 repeats. Sequencing 
the genomic DNA of this patient revealed a single 
base substitution of a T to a G at amino acid position 
186. c.367T>G sequence variant is located at amino 
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Fig 2. Sequence alignment of frataxin sequences from the human, chimpanzee, 
mouse, cow, and rattus for p.Y123D mutation in exon 3
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